4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00862680|
Recruitment Status : Completed
First Posted : March 17, 2009
Last Update Posted : April 14, 2020
|Condition or disease||Intervention/treatment|
|Metastatic Malignant Neoplasm in the Liver Metastatic Malignant Neoplasm in the Lung Stage IV Colorectal Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8||Procedure: 4-Dimensional Computed Tomography Procedure: 4D PET Scan|
|Study Type :||Observational|
|Actual Enrollment :||75 participants|
|Official Title:||4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis|
|Actual Study Start Date :||March 12, 2009|
|Actual Primary Completion Date :||April 28, 2019|
|Actual Study Completion Date :||April 28, 2019|
Diagnostic (4D PET/CT)
Participants undergo 4D PET/CT scan over up to 12 minutes.
Procedure: 4-Dimensional Computed Tomography
Undergo 4D PET/CT
Procedure: 4D PET Scan
Undergo 4D PET/CT scan
- Maximum lesion standardized uptake value (SUVmax) for gated and ungated positron emission tomography/computed tomography (PET/CT) scans [ Time Frame: Up to 10 years ]Will be compared using a one-sided paired t-test.
- Impact of the difference in SUVmax on the lesion detectability and staging of the evaluated patients [ Time Frame: Up to 10 years ]two nuclear medicine physicians will assess the impact of the difference in SUVmax on the lesion detectablility and staging of the evaluated patients.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00862680
|United States, Texas|
|M D Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Osama Mawlawi||M.D. Anderson Cancer Center|